Daniela Shveid Gerson
@DSG_MD
Followers
360
Following
754
Media
49
Statuses
627
MD, MSc 💜 Clinical oncology. Translational research, building patient relations 👥. Students are the best teachers.
Mexico City, MX
Joined April 2022
In a joint work between hematology and oncology we present this narrative review Thank you @mistralCM @taliawegman @DSG_MD @trejo_becer Somatic Landscape of Oncogenic Variants Across the Main Cancer Subtypes in Latin America:
ascopubs.org
Variations in somatic genetic alterations can be observed across different cancer types and diverse populations. Understanding the frequency of oncogenic variants in specific populations helps...
1
3
9
In ongoing care, clinical documentation, the most important part is to be told what the author is thinking. what is available elsewhere or the historic aspect is of much lower relevance.
6
4
30
Awareness, Knowledge & Treatment Patterns of Non-Metastatic Inflammatory #breastcancer in Low & Middle-Income Countries: The BRIDGES Study ➡️ https://t.co/q0Slu49aG2 Co-authors: @stolaney1 @curijoey @jenniferbellon2 @DSG_MD @inas_md @SarahSewar @jamecancerdoc @DFCI_BreastOnc
ascopubs.org
PURPOSETrimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy...
0
8
13
https://t.co/DYEZx1unxN Grateful for amazing global 🌎collaborators that made this possible: @darioT_ @FilipaLynce @stolaney1 @curijoey @DSG_MD @inas_md @SarahSewar @jamecancerdoc @EnriqueSoto8 @Otto_DFCI @DFCI_BreastOnc @IBC_DanaFarber @OncoAlert
ascopubs.org
PURPOSETrimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy...
0
9
24
The BRIDGES study is now @JCOGO_ASCO ❓ Management of IBC in low and middle income countries ✅ 112 responses from clinicians from 36 counties 🔑 1/3 of patients with non metastatic IBC are receiving TMT 🔑 provider education everywhere is key to improve patient outcomes
3
8
27
Thank you @DSG_MD for inviting me to give grand rounds at the Centro Médico ABC in Mexico City ⭐️
1
3
22
Updated (non-exhaustive) breast cancer treatment algorithms, now including adjuvant ribociclib and other recent updates. I am happy to be running out of space as treatment options continue to expand! @OncoAlert #bcsm
13
151
495
Mucha participación en el Seminario OMI-MEX CHOP de Liderazgo Médico 2024 #seminario #seminarios #medicina #medicos #médico #médicos #salud #health
0
1
1
Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in @NatureComms. https://t.co/e5AYdyrnbx 🧵
5
172
468
10 days to Xmas🎄....and less than 4 weeks to #GI24 @ASCO 🙌 Here are the key #GI #abstracts I am waiting for👇 Special Mentions 🌟NETTER2 - Dr. Simron Singh🇨🇦 #NET 🌟COBRA (NRG GI-005) - @VanMorrisMD
@CDNCancerTrials @howiel2013 #CRCsm #ctDNA Congrats to #GI24 planning
3
25
61
2023 was an outstanding year for breast cancer research As we start wrapping up #SABCS23, we need to think about how to incorporate what we learned in the clinic and future research. Looking forward to what is yet to come to improve outcomes for our patients! @OncoAlert #BCSM
10
154
354
Great international collaboration!! 🇧🇷🇲🇽🇮🇹🇪🇸🌍Great to see Mexican representation @INCMNSZ_Uronco
Just out! SII index as a prognostic tool for mRCC in the immune combos era. Thanks all ARON team for the support. @fmassari79 @drenriquegrande @BourlonMaite @DrAndreFay @CPRT65 @JaviMolinaC
https://t.co/2Fd5IxDvU5
3
10
43
Así se vivió el curso corto de actualización de genética y genómica para el oncólogo. ¡Agradecemos a todos los asistentes! . . #smeo #sociedadmexicanadeoncología #médicosoncólogos #genéticaygenómica #oncology #oncología #cursocorto
0
2
6
Day 1 #ESMO23 Highlights #CommunityOncology NSCLS 1. #CM816 @DrMarkAwad 2. #KN671 @DoctorJSpicer 3. #ATTLAS Breast Ca 4. #MonarchE #bcsm 5. #KN756/#CM7FL @LoiSher 6. #KN522 TNBC @JavierCortesMD
#lcsm #OncTwitter @myESMO #OncEd @OncoAlert @DrSGraff @g_mountzios 1/7
6
79
226
#ESMO23 Day2 ⚡️🔥 #CommunityOncology 1. DB04 ⬇️Her2 #bcsm
#NSCLC 2. #ALINA ALK+ @bensolomon1 3. #LIBRETTO431 RET+ 4. #PAPILLON Exon20 5. #CM77T ✂️ 6. #LITESPARK005 Belzutifan-RCC @DrChoueiri 7. #SPOTLIGHT Cldn18.2 #gism
#OncTwitter #MedTwitter @myESMO #lcsm 1/8
2
53
116
0
1
5
Past/present: ADAURA in EGFR+ Present/Future: ALINA in ALK+ Future: LIBRETTO-432 in RET+ NSCLC? Several clinical Qx ADJ TKI if minimal residual disease? Or for those w/oMRD? Improving worldwide inequalities @EGFRResisters @ALKPositiveinc @RETpositive @EGFRmNSCLC
@OncoAlert
1
56
128